Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.

被引：5
|
作者：
Mansoor, Wasat [1 ]
Kulkarni, Amit S. [2 ]
Kato, Ken [3 ]
Sun, Jong-Mu [4 ]
Shah, Manish A. [5 ]
Enzinger, Peter C. [6 ]
Adenis, Antoine [7 ]
Doi, Toshihiko [8 ]
Kojima, Takashi [9 ,10 ]
Metges, Jean-Philippe
Li Zhigang [11 ]
Kim, Sung-Bae [12 ]
Cho, Byoung Chul [13 ]
Sunpaweravong, Patrapim [14 ]
Alsina, Maria [15 ,16 ]
Goekkurt, Eray [17 ,18 ]
Suryawanshi, Shailaja [2 ]
Norquist, Josephine [2 ]
Shah, Sukrut [2 ]
Shen Lin [19 ]
机构：
[1] Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Natl Canc Ctr, Tokyo, Japan
[4] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[5] Weill Cornell Med, New York, NY USA
[6] Dana Farber Canc Inst, Ctr Esophageal & Gastr Canc, Boston, MA 02115 USA
[7] Univ Montpellier, IRCM, INSERM, ICM, Montpellier, France
[8] Natl Canc Ctr Hosp East, Chiba, Japan
[9] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[10] CHU Brest, Inst Cancerol & Hematol ARPEGO Network, Brest, France
[11] Shanghai Chest Hosp Esophageal Dis Ctr, Shanghai, Peoples R China
[12] Asan Med Ctr, Seoul, South Korea
[13] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[14] Prince Songkla Univ Hosp, Songkhla, Thailand
[15] Vall dHebron Univ Hosp, Barcelona, Spain
[16] Inst Oncol VCIO, Barcelona, Spain
[17] Hematol Oncol Practice Eppendorf, Hamburg, Germany
[18] Univ Canc Ctr Hamburg, Hamburg, Germany
[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.
    Vaughn, David J.
    Bellmunt, Joaquim
    De Wit, Ronald
    Fradet, Yves
    Lee, Jae-Lyun
    Fong, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [32] Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
    Cescon, David W.
    Schmid, Peter
    Rugo, Hope S.
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Perez-Garcia, Jose
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Haiderali, Amin
    Zhou, Xuan
    Guo, Zifang
    Nguyen, Allison Martin
    Cortes, Javier
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (05): : 717 - 727
  • [33] The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer
    Metges, J.
    Francois, E.
    Shah, M.
    Adenis, A.
    Enzinger, P.
    Kojima, T.
    Muro, K.
    Bennouna, J.
    Hsu, C.
    Moriwaki, T.
    Kim, S.
    Lee, S.
    Kato, K.
    Shen, L.
    Qin, S.
    Ferreira, P.
    Wang, R.
    Bhagia, P.
    Kang, S.
    Doi, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results
    Janjigian, Yelena Y.
    Kawazoe, Akihito
    Xu, Jianming
    Lonardi, Sara
    Metges, Jean-Philippe
    Wyrwicz, Lucjan S.
    Shen, Lin
    Ostapenko, Yuriy
    Bilici, Mehmet
    Lowery, Maeve Aine
    Valderrama, Adriana
    Guan, Yanfen
    Li, Kan
    Shih, Chie-Schin
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 286 - 286
  • [35] Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
    Lee, Keun-Wook
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Lee, Jeeyun
    Castro, Hugo R.
    Chao, Joseph
    Wainberg, Zev A.
    Cao, Z. Alexander
    Aurora-Garg, Deepti
    Kobie, Julie
    Cristescu, Razvan
    Bhagia, Pooja
    Shah, Sukrut
    Tabernero, Josep
    Shitara, Kohei
    Wyrwicz, Lucjan
    CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3489 - 3498
  • [36] Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.
    De Wit, Ronald
    Bajorin, Dean F.
    Bellmunt, Joaquim
    Fradet, Yves
    Lee, Jae-Lyun
    Fong, Lawrence
    Vogelzang, Nicholas J.
    Climent, Miguel Angel
    Petrylak, Daniel Peter
    Choueiri, Toni K.
    Necchi, Andrea
    Gerritsen, Winald R.
    Gurney, Howard
    Quinn, David I.
    Culine, Stephane
    Sternberg, Cora N.
    Mai, Yabing
    Li, Haojie
    Perini, Rodolfo F.
    Vaughn, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
    Shitara, Kohei
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles
    Wyrwicz, Lucjan
    Lee, Keun-Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Lee, Jeeyun
    Castro, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Caglevic, Christian
    Villanueva, Luis
    Goekkurt, Eray
    Satake, Hironaga
    Enzinger, Peter
    Alsina, Maria
    Benson, Al
    Chao, Joseph
    Ko, Andrew H.
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, S. Peter
    Tabernero, Josep
    JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580
  • [38] First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
    Marth, Christian
    Moore, Richard G.
    Bidzinski, Mariusz
    Pignata, Sandro
    Ayhan, Ali
    Rubio, M. Jesus
    Beiner, Mario
    Hall, Marcia
    Vulsteke, Christof
    Braicu, Elena Ioana
    Sonoda, Kenzo
    Wu, Xiaohua
    Frentzas, Sophia
    Mattar, Andre
    Lheureux, Stephanie
    Chen, Xiaojun
    Hasegawa, Kosei
    Magallanes-Maciel, Manuel
    Choi, Chel Hun
    Shalkova, Mariia
    Kaen, Diego
    Wang, Peng-Hui
    Berger, Regina
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Yao, Lili
    Orlowski, Robert
    Khemka, Vivek
    Gilbert, Lucy
    Makker, Vicky
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
  • [39] Re: Health-Related Quality-of-Life Analysis from KEYNOTE-045: A Phase III Study of Pembrolizumab versus Chemotherapy for Previously Treated Advanced Urothelial Cancer Editorial Comment
    Resnick, Matthew J.
    JOURNAL OF UROLOGY, 2019, 201 (01): : 22 - 22
  • [40] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
12345